A small study suggests the use of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with mantle cell lymphoma (MCL) with secondary central nervous system (CNS) involvement is safe ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said. Treatment with CAR-T cell therapy Breyanzi ...

ATLANTA--(BUSINESS WIRE)--Cellworks Group, Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced clinical study results using the ...

Mantle cell lymphoma (MCL) is rare and difficult to manage, since it can range from a slow-growing disease to an aggressive form that is difficult to control. Fortunately, a new wave of treatments and ...

Evolving Paradigms in the Treatment of Philadelphia Chromosome–Positive ALL Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous B-cell malignancy with variable prognosis, ranging ...

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell ...

As in CLL, immunoglobulin heavy chain genes are mutated in a subset of MCL patients, but, in contrast to CLL, this does not seem to correlate with outcome. Recent data, however, suggest that using a ...